Regal One Client Neuralstem, Inc. Completes $5 Million Private Placement

Regal One Corporation, Inc. (OTC BB: RONE), which on January 20, 2006 announced an equity-share purchase agreement with Neuralstem, Inc., said today its client Neuralstem had raised $5 million in a private placement, and plans to file a registration statement with the SEC over the next 30 days so that it can become a publicly traded company.

TR Winston & Company acted as placement agent for the offering, with significant participation from S W Bach & Co. The placement consisted of 5 million units priced at $1.00 per unit, each unit including one share of Neuralstem common stock, 1/2 "A" Warrant to purchase a share of common stock at $1.50, and 1/2 "B" warrant for the purchase of common stock at $2.00 per share.

Based in Rockville, Maryland, Neuralstem has a mission to cure diseases of the central nervous system (CNS) utilizing patented human neural stem cell technology developed by founding scientist Dr. Karl Johe. Major CNS diseases targeted by the Company with research programs currently underway include: ischemic spastic paraplegia, traumatic spinal cord injury, ALS, and Parkinson's disease.

Neuralstem's patent-protected technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercially reasonable quantities, and to control the differentiation of these cells into mature, physiologically relevant human neurons and glia.

Currently, Neuralstem has 24,520,875 common shares issued and outstanding, of which approximately 1.8 million are owned by Regal One Corporation. Regal's board has approved a dividend of 500,000 shares of its Neuralstem stock to be distributed to Regal One shareholders of record as of February 15, 2006. Neuralstem plans to file an SB-2 registration over the next 30 days. The distribution of Neuralstem common shares to Regal One shareholders will take place after the registration statement has been declared effective so that the shares would be freely tradable at that time.

Regal One, through its network of advisors and consultants, assisted Neuralstem in completing two previous rounds of preliminary financing. Regal One's Chairman and CEO, Dr. Malcolm Currie, has agreed to serve on the Board of Directors of Neuralstem, and to assist in the recruitment of additional independent directors.

Dr. Currie said, "Regal One whole-heartedly endorses Neuralstem's election to become a public company. We feel it will offer the public an opportunity to participate in one of the most exciting and productive areas in the life sciences today -- neural stem cells -- with best of breed science and important near-term applications."

Neuralstem intends to complete its ongoing animal studies for its first indication this spring and, on the basis of these studies, file an Investigational New Drug (IND) application during the summer of 2006. Upon approval of the IND, the company hopes to begin a human feasibility study/clinical trial before the end of the 2006 calendar year.

About Regal

Since June 15, 2005, Regal One has been matriculating as a Business Development Corporation 100% focused on recruiting, coaching and bringing public next-generation biomedical companies. Regal One seeks biomedical companies with world class, distinctive IP and well-defined, near-term applications that address significant and quantifiable markets. Based in Los Angeles, California, the company provides qualified candidates access to best-of-breed advisors, and the shortest, least expensive path to public liquidity. Regal One is led by Dr. Malcolm Currie, former Under Secretary of Defense, Chairman and CEO of Hughes Aircraft (now Hughes Electronics), and Chairman of the University of Southern California (USC) Board of Trustees.

This press release contains forward-looking statements. Regal One wishes to caution the readers of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, the need to raise additional capital, the corporate activities of Neuralstem, Inc., SEC responses to various registration submissions, US FDA responses to various regulatory submissions, and the market for stem cell research in general. For further information, please review the company's 10-QSB and 10-KSB filings with the Securities and Exchange Commission.

Distributed by Market Wire